NEW YORK – CareDx said on Friday that it has received CE marking for its AlloSeq Tx 17 HLA typing product.
AlloSeq Tx 17, which the company launched in September 2019, is used to match transplant donor organs to recipients using next-generation hybrid capture technology for HLA testing. During CareDx's fourth quarter earnings conference call in February, Chairman and CEO Peter Maag said that the company expects the AlloSeq Tx HLA typing product to start driving product revenues this year, and that it received high marks from beta testers before it was officially launched.
"AlloSeq Tx 17 eliminates PCR disadvantages such as allele drop out and provides a simple workflow that could be easily implemented in histocompatibility and immunogenetics laboratories," Milena Ivanova-Shivarova, lab manager of Alexandrovska University Hospital, said in a statement. "Generation of reliable data and ability to extend the typing to additional non-classical HLA loci will provide better care for patients."